RANI
Rani Therapeutics Holdings, Inc.
Biotechnology · Healthcare · United States
0.59
close · 2026-10-30
value
8
cheaper than peers8
quality
25
stronger fundamentals25
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.69× | 76 |
| price to sales | 17.00× | 41 |
| cash flow yield, latest year | -22.7% | 32 |
| cash flow yield, 1 year ago | -43.1% | 20 |
| cash flow yield, 3 years ago | -58.1% | 16 |
| cash flow yield, 2 years ago | -63.3% | 16 |
| earnings yield, latest year | -76.3% | 14 |
| earnings yield, 2 years ago | -225.4% | 9 |
| earnings yield, 3 years ago | -216.9% | 9 |
| earnings yield, 1 year ago | -178.0% | 8 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 7.4% | 67 |
| operating margin | -516.9% | 34 |
| return on equity | -172.1% | 14 |
3 of 4 measures available
Facts
| market cap | $83M |
| free cash flow | -$8.9M |
| employees | 69 |
| first trade | 2021-07-30 |
| next earnings | not reported |
| fundamentals updated | 2026-08-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.45 | -1.05 | -1.33 | -1.28 |
| free cash flow | -$18.8M | -$35.8M | -$52.5M | -$48.1M |
| net income | -$29.7M | -$30.0M | -$34.0M | -$30.6M |
| revenue | $1.6M | $1.0M | $0 | $0 |
| unusual items | -$576,000 | -$3.7M | $0 | $0 |